- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00441207
Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors
A Phase I Study of High-Dose IV Vitamin C Treatment in Patients With Solid Tumors
The primary purpose of this study is to evaluate the safety and tolerability of vitamin C (ascorbic acid) given by injection into the vein.
The second and third purpose of conducting this study is to observe any evidence of tumor response to the vitamin C and compare the level of fatigue (weakness), pain control, ability to do things, and quality of life, before and after vitamin C is given.
Study Overview
Detailed Description
Preclinical studies of pharmacologic doses of vitamin C (ascorbic acid, ascorbate) have shown significant anticancer effects in animal models and tissue culture investigations including cytotoxic effects in certain cancer cell lines at micromolar to millimolar concentrations.
Early clinical studies have shown that intravenous and oral doses of vitamin C may improve symptoms and prolong survival in terminal cancer patients. More recent double-blind placebo-controlled studies have shown that oral adminstration of vitamin C provides no benefit to cancer patients. Conversely, intravenous vitamin C administration raises plasma concentrations as high as 14 mM/L, and concentrations of 1-5 mM/L have been found to be selectively cytoxic to tumor cells in vitro.
The proposed Phase I trial with vitamin C should achieve millimolar concentrations of vitamin C that have been shown to kill tumor cells in vitro. The maximum tolerated dose (MTD), PK, possible drug accumulation with repeated dosing, quality of life, pain response, fatigue status, and hints of efficacy in patients with advanced cancer will be examined.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Zion, Illinois, United States, 60099
- CTCA @ Midwestern Regional Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Primary histological diagnosis of advanced solid tumors (stage 3 and 4) and measurable disease.
- Disease must have progressed for which no available treatment provides clinical benefit.
- 18 years of age or older.
- No scheduled cancer therapy (chemotherapy, hormonal therapy, immune therapy, or radiation therapy) for three months after study entry, and the subject must have had their last therapy at least four (4) weeks prior to entry to this study.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Informed Consent - The patient must be willing and able to sign the informed consent prior to the start of the trial.
- Willingness to comply with the weekly phone calls between office visits.
- Willingness to undergo central line placement (e.g., port-a-catheter, central venous catheter, percutaneously inserted central catheter [PICC] line placement) and able to manage care of the entry site safely.
- Patients must be able to take food orally or have peg tube for feeding.
- Life expectancy of at least 3 months.
Exclusion Criteria:
- Glucose-6-phosphate dehydrogenase deficiency (G6PD) (a relative contraindication)
- Renal insufficiency as evidenced by serum creatinine of ≥ 1.3 mg/dl or evidence of oxalosis by urinalysis.
- Chronic hemodialysis.
- Iron overload (a ferritin > 500 ng/ml).
- Wilson's disease.
- Compromised liver function with evidence of complete biliary obstruction or have a serum bilirubin of 2.0 or liver function tests (AST > 63, ALT > 95) exceeding 1.5 x the upper limit of normal.
- Pregnant or lactating female.
- Current tobacco use.
- Evidence of significant psychiatric disorder by history or examination that would prevent completion of the study or preclude informed consent.
- Aspirin use exceeding 325 mg per day.
- Acetaminophen use exceeding 2 g per day.
- Brain metastases that have not responded to therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the safety and tolerability of high dose IV vitamin C as a monotherapy
Time Frame: 1-1/2 years
|
1-1/2 years
|
Evaluate the pharmacokinetic profile of IV vitamin C at varying doses
Time Frame: 1-1/2 years
|
1-1/2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine if vitamin C accumulates with repeated daily therapy by measuring peak and nadir levels
Time Frame: 1 year
|
1 year
|
Evaluate patient quality of life
Time Frame: Duration of Study
|
Duration of Study
|
Observe patients for clinical and radiological evidence of anti-tumor activity at the end of treatment
Time Frame: Duration of Study
|
Duration of Study
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christopher Lis, Midwestern Regional Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTCA 06-04
- Ascorbic Acid Injection
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
University of Wisconsin, MadisonCompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject | Stage I Colorectal Cancer | Stage IIIA Colorectal Cancer | Stage IIIB Colorectal Cancer | Stage... and other conditionsUnited States
Clinical Trials on Ascorbic Acid
-
Harokopio UniversityCompletedSymptomatic Knee OsteoarthritisGreece
-
Situs Cancer Research CenterSuspendedSarcoma | Adenocarcinoma | Carcinoma | Multiple Myeloma | Desmoplastic Small Round Cell TumorUnited States
-
DongGuk UniversityKorean Association For Vitamin ResearchCompleted
-
National Taiwan University Hospital Hsin-Chu BranchCompletedHemodialysis Access Failure
-
Sisli Hamidiye Etfal Training and Research HospitalCompletedCovid19 | Respiratory Distress Syndrome, AdultTurkey
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Unknown
-
Jewish General HospitalCompleted
-
Swiss Federal Institute of TechnologyCompletedIron-deficiency | Iron Deficiency AnemiaSwitzerland
-
Cairo UniversityCompletedPalatally Impacted CaninesEgypt